BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

397 related articles for article (PubMed ID: 18065233)

  • 1. Three-dimensional quantitative structure-activity relationship studies on novel series of benzotriazine based compounds acting as Src inhibitors using CoMFA and CoMSIA.
    Gueto C; Ruiz JL; Torres JE; Méndez J; Vivas-Reyes R
    Bioorg Med Chem; 2008 Mar; 16(5):2439-47. PubMed ID: 18065233
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 3D-QSAR CoMFA/CoMSIA studies on 5-aryl-2,2-dialkyl-4-phenyl-3(2H)-furanone derivatives, as selective COX-2 inhibitors.
    Puntambekar DS; Giridhar R; Yadav MR
    Acta Pharm; 2006 Jun; 56(2):157-74. PubMed ID: 16613723
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 3D-QSAR CoMFA/CoMSIA studies on Urokinase plasminogen activator (uPA) inhibitors: a strategic design in novel anticancer agents.
    Bhongade BA; Gadad AK
    Bioorg Med Chem; 2004 May; 12(10):2797-805. PubMed ID: 15110861
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular modeling studies of phenoxypyrimidinyl imidazoles as p38 kinase inhibitors using QSAR and docking.
    Ravindra GK; Achaiah G; Sastry GN
    Eur J Med Chem; 2008 Apr; 43(4):830-8. PubMed ID: 17706839
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Insight into the structural requirements of urokinase-type plasminogen activator inhibitors based on 3D QSAR CoMFA/CoMSIA models.
    Bhongade BA; Gadad AK
    J Med Chem; 2006 Jan; 49(2):475-89. PubMed ID: 16420035
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 3D-QSAR analysis of cycloguanil derivatives as inhibitors of A16V + S108T mutant Plasmodium falciparum dihydrofolate reductase enzyme.
    Adane L; Bharatam PV
    J Mol Graph Model; 2009 Nov; 28(4):357-67. PubMed ID: 19796975
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative molecular field analysis and comparative molecular similarity indices analysis of human thymidine kinase 1 substrates.
    Bandyopadhyaya AK; Johnsamuel J; Al-Madhoun AS; Eriksson S; Tjarks W
    Bioorg Med Chem; 2005 Mar; 13(5):1681-9. PubMed ID: 15698786
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 3D QSAR studies on T-type calcium channel blockers using CoMFA and CoMSIA.
    Doddareddy MR; Jung HK; Cha JH; Cho YS; Koh HY; Chang MH; Pae AN
    Bioorg Med Chem; 2004 Apr; 12(7):1613-21. PubMed ID: 15028254
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Insights into the structural requirements of farnesyltransferase inhibitors as potential anti-tumor agents based on 3D-QSAR CoMFA and CoMSIA models.
    Puntambekar DS; Giridhar R; Yadav MR
    Eur J Med Chem; 2008 Jan; 43(1):142-54. PubMed ID: 17448576
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CoMFA and CoMSIA 3D QSAR analysis on N1-arylsulfonylindole compounds as 5-HT6 antagonists.
    Doddareddy MR; Cho YS; Koh HY; Pae AN
    Bioorg Med Chem; 2004 Aug; 12(15):3977-85. PubMed ID: 15246074
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Insight into the structural requirements of proton pump inhibitors based on CoMFA and CoMSIA studies.
    Nayana MR; Sekhar YN; Nandyala H; Muttineni R; Bairy SK; Singh K; Mahmood SK
    J Mol Graph Model; 2008 Oct; 27(3):233-43. PubMed ID: 18676164
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Three-dimensional quantitative structure-activity relationship CoMSIA/CoMFA and LeapFrog studies on novel series of bicyclo [4.1.0] heptanes derivatives as melanin-concentrating hormone receptor R1 antagonists.
    Morales-Bayuelo A; Ayazo H; Vivas-Reyes R
    Eur J Med Chem; 2010 Oct; 45(10):4509-22. PubMed ID: 20691511
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Docking, 3D-QSAR studies and in silico ADME prediction on c-Src tyrosine kinase inhibitors.
    Tintori C; Magnani M; Schenone S; Botta M
    Eur J Med Chem; 2009 Mar; 44(3):990-1000. PubMed ID: 18722033
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CoMFA and CoMSIA 3D-QSAR studies on quionolone caroxylic acid derivatives inhibitors of HIV-1 integrase.
    Lu P; Wei X; Zhang R
    Eur J Med Chem; 2010 Aug; 45(8):3413-9. PubMed ID: 20488589
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 3D-QSAR studies of boron-containing dipeptides as proteasome inhibitors with CoMFA and CoMSIA methods.
    Zhu YQ; Lei M; Lu AJ; Zhao X; Yin XJ; Gao QZ
    Eur J Med Chem; 2009 Apr; 44(4):1486-99. PubMed ID: 18771818
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 3D QSAR studies on protein tyrosine phosphatase 1B inhibitors: comparison of the quality and predictivity among 3D QSAR models obtained from different conformer-based alignments.
    Pandey G; Saxena AK
    J Chem Inf Model; 2006; 46(6):2579-90. PubMed ID: 17125198
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Understanding the antitumor activity of novel tricyclicpiperazinyl derivatives as farnesyltransferase inhibitors using CoMFA and CoMSIA.
    Puntambekar DS; Giridhar R; Yadav MR
    Eur J Med Chem; 2006 Nov; 41(11):1279-92. PubMed ID: 16919851
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CoMFA and CoMSIA studies on HIV-1 attachment inhibitors.
    Lu P; Wei X; Zhang R
    Eur J Med Chem; 2010 May; 45(5):1792-8. PubMed ID: 20149491
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 3D-QSAR studies on the inhibitors of AP-1 and NF-kappaB mediated transcriptional activation.
    Qin J; Liu H; Li J; Ren Y; Yao X; Liu M
    Eur J Med Chem; 2009 Jul; 44(7):2888-95. PubMed ID: 19128859
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Three-dimensional QSAR analyses of 1,3,4-trisubstituted pyrrolidine-based CCR5 receptor inhibitors.
    Zhuo Y; Kong R; Cong XJ; Chen WZ; Wang CX
    Eur J Med Chem; 2008 Dec; 43(12):2724-34. PubMed ID: 18538451
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.